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Regulatory T cells play a key role in suppress-
ing immune responses and in maintaining im-
munological homeostasis. Regulatory T cells 
have been shown to prevent autoimmune dis-
eases, to down-modulate immune response to 
allergens, pathogens, and cancer cells, and to 
mediate peripheral transplantation tolerance 
(1–7). The best characterized subset of regula-
tory T cells are the CD4+CD25+FOXP3+ 
natural regulatory T (nTreg) cells, whose dif-
ferentiation, maintenance, and function are 
controlled by TCR engagement (8, 9), CD28 
engagement (10, 11), FOXP3 (12, 13), and IL-2 
(14, 15). nTreg cells are generated in the thy-
mus upon TCR–peptide–MHC interaction (9) 
as a cell population with a broad repertoire of 
high-affi   nity TCRs, recognizing self-antigens 
(9, 16), tumor-associated antigens (17), allogeneic 
antigens (18), and possibly pathogen-derived 
antigens (19). Recent fi   ndings indicate that 
nTreg cells derive from high-affi   nity autoreac-
tive T cells, which upon contact with a subset 
of activated DCs within the Hassal’s corpuscles 
in the thymic medulla (20) acquire regulatory 
function. nTreg cells are readily present in the 
thymus, blood, and secondary lymphoid organs 
of healthy individuals or mice and represent 
5–10% of the total CD4+ T cells (2). The 
mechanisms by which nTreg cells are activated 
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A large proportion of Wiskott-Aldrich syndrome (WAS) patients develop autoimmunity and 
allergy. CD4+CD25+FOXP3+ natural regulatory T (nTreg) cells play a key role in peripheral 
tolerance to prevent immune responses to self-antigens and allergens. Therefore, we inves-
tigated the effect of WAS protein (WASP) defi  ciency on the distribution and suppressor 
function of nTreg cells. In WAS−/− mice, the steady-state distribution and phenotype of 
nTreg cells in the thymus and spleen were normal. However, WAS−/− nTreg cells engrafted 
poorly in immunized mice, indicating perturbed homeostasis. Moreover, WAS−/− nTreg cells 
failed to proliferate and to produce transforming growth factor 𝗃 upon T cell receptor 
(TCR)/CD28 triggering. WASP-dependent F-actin polarization to the site of TCR triggering 
might not be involved in WAS−/− nTreg cell defects because this process was also ineffi  -
cient in wild-type (WT) nTreg cells. Compared with WT nTreg cells, WAS−/− nTreg cells 
showed reduced in vitro suppressor activity on both WT and WAS−/− effector T cells. Simi-
larly, peripheral nTreg cells were present at normal levels in WAS patients but failed to 
suppress proliferation of autologous and allogeneic CD4+ effector T cells in vitro. Thus, 
WASP appears to play an important role in the activation and suppressor function of nTreg 
cells, and a dysfunction or incorrect localization of nTreg cells may contribute to the devel-
opment of autoimmunity in WAS patients.
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and mediate suppression of eff  ector CD4+ and CD8+ T cells 
are still under investigation. Activation of nTreg cells is trig-
gered by engagement of TCR and requires IL-2 (8, 21). In 
vitro suppressor activity of nTreg cells is mediated predomi-
nantly by cell–cell contact mechanisms. It remains to be clari-
fi  ed which are the molecules responsible for this process. 
A role for membrane-bound TGF-β (22) and CTLA-4 (23) 
in mediating nTreg cell suppressor function was hypothe-
sized, but it appears to be limited to specifi  c in vitro settings 
and was not confi  rmed by follow-up studies (24, 25). A pos-
sible additional mechanism of suppression could be via the 
release of perforin and granzyme by nTreg cells, resulting in 
apoptosis of eff  ector T cells (26, 27). In addition, secretion of 
TGF-β (28, 29) and IL-10 (30) can contribute to the sup-
pressor activity of nTreg cells in vivo. Quantitative and quali-
tative defects in regulatory T cells may result in pathology. 
Indeed, there is evidence that skewing of antigen-specifi  c T 
cells toward a regulatory instead of a Th1 or Th2 phenotype 
is key in the maintenance of homeostasis and in the preven-
tion of autoimmunity (31) and allergy (32).
Wiskott-Aldrich syndrome (WAS) is a primary human 
X-linked immunodefi   ciency caused by mutations in the 
WAS protein (WASP) (33) and characterized by recurrent 
infections and thrombocytopenia. A high proportion of WAS 
patients develop eczema and have high IgE levels (34), sug-
gesting a Th2 unbalance. This is in line with the recent fi  nd-
ing that WAS T cell lines have a selective defect in Th1 
cytokine production (35) and that WAS−/− mice develop a 
skewed Th2 phenotype (Snapper, S.B., personal communi-
cation). Moreover, WAS patients lacking WASP expression 
have an increased risk of developing autoimmune diseases, 
including hemolytic anemia, cutaneous vasculitis, IgA nephropa-
thy, infl  ammatory bowel disease, and arthritis (34, 36). WASP 
is a tightly regulated hematopoietic-specifi  c protein, which 
controls actin nucleation (37), immunological synapse assembly 
(38), and migration to secondary lymphoid organs (39). In 
addition, WASP regulates apoptosis (40), proliferation, and 
IL-2 production in eff  ector T cells (41–44). Although these 
defects contribute to the immunodefi  ciency, it cannot be ex-
cluded that defects in regulatory T cell populations and func-
tion are associated with the development of autoimmunity 
and with the unbalanced Th2 response in WAS patients. To 
determine whether the absence of WASP is associated with 
nTreg cell dysfunction, we characterized nTreg cells isolated 
from WAS−/− mice and WAS patients. In WAS−/− mice, 
the diff  erentiation of nTreg cells and their steady-state distri-
bution to secondary lymphoid organs were not signifi  cantly 
impaired. However, nTreg cell activation, in vitro suppres-
sive activity, and in vivo engraftment were strongly reduced. 
Similarly, in WAS patients the frequency of peripheral nTreg 
cells was normal, but they displayed poor suppressor activity 
toward normal and WASP-defi  cient eff  ector T cells in vitro. 
These data demonstrate that WASP is a major regulator of 
nTreg cell activation and function, suggesting that the auto-
immune and atopic pathological manifestations in WAS may 
result from this impairment.
RESULTS
WASP and F-actin fail to polarize in murine nTreg cells 
after TCR triggering
To investigate whether WASP plays a role in the function of 
nTreg cells, we fi  rst analyzed WASP expression and localiza-
tion in mouse WT nTreg cells. nTreg cells from the spleens 
of C57BL/6 mice express WASP at levels comparable to that 
of CD4+CD25− T cells, CD8+ T cells (Fig. 1 a), B cells, NK 
cells, and granulocytes (not depicted). We previously showed 
that WASP promotes actin polarization at the immunologi-
cal synapse of eff  ector T cells (38). Accordingly, after activa-
tion of WT CD4+CD25− eff  ector T cells with WT APCs in 
the presence of anti-CD3 mAbs, F-actin and WASP polar-
ized to the APC contact site in  50% of the conjugates (Fig. 
1, b and c). In contrast, <10% of CD4+CD25+ WT nTreg 
Figure 1.  WASP expression in murine nTreg cells. (a) WASP expres-
sion in CD4+CD25+, CD4+CD25−, and CD8+ T cells. Splenocytes from WT 
mice were stained with anti-WASP mAbs (fi  lled histogram) or isotype 
matched control antibodies (empty histogram) and gated on the indicated 
T cell subset. Numbers indicate percentages and MFI of WASP+ cells. 
(b) F-actin and WASP localization in murine splenic WT CD4+CD25− and 
CD4+CD25+ T cells upon stimulation. CD4+CD25− effector T cells (left) 
and CD4+CD25+ nTreg cells (right) were stimulated with WT APCs 
(stained in orange) in the absence or presence of 10 μg/ml anti-CD3 
mAbs. Images showing F-actin staining (left column), WASP staining 
(middle column), and their bright fi  eld overlay (right column) are shown. 
These images are representative of at least 100 T cell–APC conjugates that 
were evaluated for each experimental condition. White arrows indicate 
F-actin and WASP polarization at the T cell–APC interface. (c) Percentage of 
WT CD4+CD25+ nTreg cells and WT CD4+CD25− effector T cells showing 
F-actin polarization at the T cell–APC interface in the presence of APCs 
and in the absence or presence of the indicated amount of anti-CD3 
mAbs. Histogram bars represent the average percentage (± SD) of F-actin 
polarization in T cells from three independent experiments. *, P < 0.05, 
Student’s t test. JEM VOL. 204, February 19, 2007  371
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cells polarized F-actin and WASP at the contact of APCs. In 
most nTreg cells, a ring-like distribution of F-actin and 
WASP   beneath the plasma membrane was observed (Fig. 
1 b). The reduced polarization of F-actin and WASP in 
nTreg cells was not due to their defective ability to form 
conjugates with APCs because similar proportions of nTreg 
cells and eff  ector T cells were in contact with APCs (not 
  depicted). These data indicate that murine nTreg cells   express 
levels of WASP similar to those of CD4+CD25− eff  ector T 
cells, but they do not effi   ciently polarize F-actin and WASP 
to the APC contact site upon TCR triggering, suggesting 
that WASP-dependent actin polarization at the immuno-
logical synapse does not   occur in nTreg cells under these in 
vitro conditions.
Normal differentiation and steady-state tissue distribution 
of nTreg cells in WAS−/− mice
To determine whether WASP is required for nTreg cell 
  development, Foxp3 expression was analyzed in double nega-
tive, double positive, CD4+ single positive, and CD8+ single 
positive thymocytes of WAS−/− mice. Comparable propor-
tions of Foxp3-expressing CD4+ single positive and double 
positive thymocytes were observed in WT and WAS−/− 
mice. The vast majority of CD24loFoxp3+ mature thymo-
cytes were contained in the CD4+ single positive T cells in 
both WT and WAS−/− mice (Fig. 2 a). In addition, the over-
all thymic cellularity was similar in WT and WAS−/− mice 
(not depicted). Moreover, the relative percentages and abso-
lute counts of CD4+CD8−CD25+ T cells, as well as the 
mean fl  uorescence intensity (MFI) of CD25, were also com-
parable (Fig. 2, b and c). A raise in the absolute count of 
CD4+CD25−Foxp3+ and CD4+CD25+Foxp3+ T cells was 
found in the thymi of WAS−/− mice as compared with WT 
controls (Fig. 2, d and e). Collectively, these data indicate 
that thymic diff  erentiation of nTreg cells can effi   ciently occur 
in WAS−/− mice.
We next investigated if WASP defi  ciency may infl  uence 
the steady-state distribution of nTreg cells into the spleen. 
The overall splenocyte count was comparable in WT and 
WAS−/− mice (not depicted). Normal percentages and numbers 
Figure 2.  Thymic generation of nTreg cells in WAS−/− mice. 
(a) Thymic development of nTreg cells in WT and WAS−/− mice. CD4/CD8 
fl  ow cytometric plots were gated on live thymocytes, total Foxp3+ cells, and 
mature CD24loFoxp3+ cells. Numbers indicate the percentage of cells in 
the respective region. Data are representative of 12 mice per group ana-
lyzed in three independent experiments. (b) Immunophenotype of CD4+ 
single positive thymocytes from representative WT and WAS−/− mice. 
Numbers indicate the percentages and MFI of CD25+ cells. (c) Percentage, 
absolute count, and MFI of CD25+ cells among CD4+ single positive thy-
mocytes. Mean ± SD of 13 mice per group are shown. (d) Foxp3 and 
CD25 expression in CD4+ single positive thymocytes. Numbers indicate 
the percentage of cells in the respective region. (e) Absolute count of the 
indicated thymocyte populations. Mean ± SD of 13 mice per group is 
shown. *, P < 0.05, Student’s t test.372  ROLE OF WASP IN CD4+CD25+FOXP3+ NTREG CELLS | Marangoni et al.
of CD4+CD25+ T cells were found in the spleens of WAS−/− 
mice, although the expression of CD25 was   reduced as com-
pared with WT mice (Fig. 3, a and b). As in the   thymus, 
the absolute count of CD4+CD25−Foxp3+ T cells increased 
in the spleens of WAS−/− mice. Conversely, the numbers of 
splenic CD4+CD25+Foxp3+ nTreg cells were comparable 
to those of normal mice, whereas an increased number of 
splenic CD4+CD25+Foxp3− T cells was observed (Fig. 3, c 
and d). Expression of the nTreg cell markers CTLA-4 and 
GITR on CD4+CD25+ splenic T cells was in the normal 
range, indicating that WAS−/− nTreg cells have a normal 
phenotype (Fig. 3 e). WAS−/− CD4+CD25+ T cells also 
  expressed normal levels of the activation markers CD69, 
CD62L, and CD45RB (Fig. 3 e). These data indicate that 
splenic nTreg cells are present in WAS−/− mice in a similar 
amount to those present in WT mice, albeit CD25 expres-
sion is reduced.
Defective suppressor activity of murine WAS−/− nTreg cells
To investigate whether WAS−/− nTreg cells are functional, 
proliferation of eff  ector T cells in the presence of WT or 
WAS−/− nTreg cells was tested. As expected, WT nTreg 
cells suppressed proliferation of WT CD90+CD25− eff  ector 
T cells activated with anti-CD3 mAbs in a cell dose–dependent 
fashion (Fig. 4 a, fi  lled bars). In contrast, WAS−/− nTreg 
cells had a reduced capacity to suppress WT eff  ector T cell 
proliferation at every ratio of eff  ector T cells to nTreg cells 
tested (Fig. 4 a, dotted vs. fi  lled bars). These data indicate 
that nTreg cells require WASP to suppress WT eff  ector 
T cells in vitro. The susceptibility of WAS−/− eff  ector T 
cells, compared with WT eff  ector T cells, to be suppressed 
by WT nTreg cells (Fig. 4 a, dashed vs. fi  lled bars) or by 
WAS−/− nTreg cells (Fig. 4 a, empty vs. fi  lled bars) was also 
tested. WAS−/− eff  ector T cells proliferated at a lower extent 
than WT eff   ector cells (median proliferation was 6,360 
and 26,380 cpm, respectively; P < 0.05 as determined by 
Mann-Whitney test). Suppression of proliferation of WAS−/− 
eff  ector T cells by WT nTreg cells was comparable to the 
suppression observed with WT eff  ector T cells when an ef-
fector T cell/nTreg cell ratio of 1:0.16 was used. At lower 
eff  ector T cell/nTreg cell ratios, suppression of WAS−/− 
  eff  ector T cells by WT nTreg cells was signifi  cantly lower 
compared with that of WT eff  ector T cells (Fig. 4 a, dashed 
vs. fi  lled bars). Similar results were obtained with WAS−/− 
nTreg cells (Fig. 4 a, empty vs. fi  lled bars). These data indi-
cate that proliferation of WAS−/− eff  ector T cells was not 
suppressed by WT or WAS−/− nTreg cells in a cell dose–
  dependent manner. This may be due to intrinsic defects of 
Figure 3.  Cell count and immunophenotype of nTreg cells in the 
spleens of WAS−/− mice. (a) Immunophenotype of CD4+ splenocytes 
from representative WT and WAS−/− mice. Numbers indicate the percent-
ages and MFI of CD25+ cells. (b) Percentage, absolute count, and MFI of 
CD25+ cells among CD4+ splenocytes. Mean ± SD of 13 mice per group 
is shown. *, P < 0.05, Student’s t test. (c) Foxp3 and CD25 expression in 
CD4+ splenocytes. Numbers indicate the percentage of cells in the re-
spective region. (d) Absolute count of the indicated splenocyte popula-
tions. Mean ± SD of 13 mice per group is shown. *, P < 0.05, Student’s 
t test. (e) Immunophenotype of nTreg cells from WT and WAS−/− mice. 
Expression of CD25 is shown together with the expression of CTLA-4, 
GITR, CD69, CD62L, and CD45RB. Negative control staining resulted in 
signal below the value of 10. Numbers indicate the percentages of cells in 
the respective regions. Data are representative of six to eight mice per 
group analyzed in two independent experiments.JEM VOL. 204, February 19, 2007  373
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WAS−/− eff  ector T cells in providing factors required for 
activation of nTreg cells.
The in vivo ability of adoptively transferred WAS−/− 
and WT nTreg cells to engraft and modulate an antigen-
specifi  c immune response upon OVA immunization in WT 
or WAS−/− mice was investigated. 7–10 d after OVA im-
munization of WT recipients, donor WT nTreg cells (trans-
ferred 1 d before immunization) represented  2% of the 
CD4+Foxp3+ (Fig. 4 b) or CD4+CD25+ cells (not depicted) 
in the draining LNs. In contrast, donor WAS−/− nTreg cells 
could not be recovered in draining LNs (Fig. 4 b). The same 
results were obtained when donor nTreg cells were counted 
in nondraining LNs, spleen, blood, liver, and lungs regardless 
of CD25 and Foxp3 expression (not depicted). Accordingly, the 
in vitro proliferative recall responses to OVA were signifi  cantly 
Figure 4.  Suppressor activity of WAS−/− nTreg cells in vitro and 
in vivo. (a) In vitro suppression of WT or WAS−/− CD90+CD25− effector 
T cells (abbreviated as WT E and WAS−/− E, respectively). Effector T cells 
were mixed with purifi  ed CD4+CD25+ nTreg cells isolated from WT or 
WAS−/− mice at the indicated ratios and stimulated with 10 μg/ml of 
plate-bound anti-CD3 mAbs. Median proliferation of effector T cells: 
WT = 26,380 cpm and WAS−/− = 6,360 cpm. Mean percentage of sup-
pression ± SEM of the indicated number of independent experiments is 
shown. *, P < 0.05, Student’s t test. (b and d) Tracking of adoptively trans-
ferred nTreg cells. Purifi  ed nTreg cells from WT or WAS−/− mice were 
adoptively transferred into WT (b) or WAS−/− (d) recipients, which were 
immunized with OVA the day after. Percentage of CD45.2-expressing do-
nor CD4+Foxp3+ cells in the draining LN was determined after 7–10 d. 
Bars represent the average value for each group. *, P < 0.05, Student’s t 
test. (c and e) In vitro recall OVA-specifi  c proliferation by total cells recov-
ered from the draining LNs of WT (c) or WAS−/− (e) mice treated as in b 
and d. When mice were killed, total LN cells were restimulated with OVA 
for 72 h. Plotted values are cpm for each individual mouse with back-
ground subtraction. Bars represent the average value for each group. 
*, P < 0.05, Student’s t test. 
Figure 5.  TCR-mediated activation of WAS−/− nTreg cells. (a) Pro-
liferation of WT and WAS−/− nTreg cells stimulated with 10 μg/ml of 
plate-bound anti-CD3 mAbs, 100 U/ml IL-2, and/or 1 μg/ml anti-CD28 
mAbs as indicated. The average cpm ± SEM of three independent experi-
ments is shown. (b) TGF-β production by WT and WAS−/− nTreg cells acti-
vated as in a. The average concentration ± SEM of three independent 
experiments is shown. (c) TCR down-regulation in nTreg cells and 
CD4+CD25− effector T cells after stimulation with anti-CD3 mAbs. Plotted 
values represent the average percentage of CD3+ cells of three mice per 
group. Error bars represent SD. For nTreg cells, *, P < 0.05. For effector 
CD4+CD25− T cells, §, P < 0.05, Student’s t test. One representative ex-
periment out of three is shown. (d and e) Suppressor activity of WT and 
WAS−/− CD4+CD25+ nTreg cells on WT (d) or WAS−/− effector T cells (e) 
stimulated with different concentrations of anti-CD3 mAbs. Effector T 
cells (E) were cocultured with nTreg cells at 1:1 ratio and stimulated with 
the indicated doses of anti-CD3 mAbs. For WT effectors, median prolifera-
tion was 46,400 cpm at 1 μg/ml anti-CD3, 35,260 cpm at 10 μg/ml anti-
CD3, and 29,000 cpm at 30 μg/ml anti-CD3. For WAS−/− effectors, 
median proliferation was 6,240 cpm at 10 μg/ml anti-CD3 and 7,630 cpm 
at 30 μg/ml anti-CD3. For each dose of anti-CD3 mAbs, mean percentage 
of suppression ± SEM is shown. For d, n > 10; for e, n > 6. *, P < 0.05, 
paired Student’s t test. 374  ROLE OF WASP IN CD4+CD25+FOXP3+ NTREG CELLS | Marangoni et al.
suppressed after adoptive transfer of WT nTreg cells, but 
not of WAS−/− nTreg cells (Fig. 4 c). Signifi  cantly lower 
percentages of CD4+Foxp3+ (Fig. 4 d) or CD4+CD25+ (not 
depicted) WAS−/− nTreg cells as compared with WT nTreg 
cells were also recovered in WAS−/− recipients (1 and 4%, 
respectively). However, both WT and WAS−/− nTreg cells 
modulated the OVA-specifi  c immune response elicited in 
WAS−/− mice, as demonstrated by the in vitro recall response 
to OVA (Fig. 4 e). It should be noted that the overall prolif-
eration of WAS−/− T cells to OVA was higher than that of 
WT T cells, even when the WAS−/− nTreg cells were trans-
ferred in vivo. Collectively, our results indicate that WASP-
defi  cient nTreg cells fail to engraft in WT and displayed a 
reduced engraftment in WAS−/− hosts, suggesting that this 
defect may contribute to their dysfunction in vivo.
Impaired TCR/CD28 activation of WAS−/− nTreg cells
Activation through the TCR is required for the suppressive 
function of nTreg cells (8). Therefore, it is possible that 
  defective suppressor activity of WAS−/− nTreg cells is due to a 
defect in their activation. To address this question, we mea-
sured the proliferative response and the cytokine secretion 
profi  le of WAS−/− nTreg cells after TCR stimulation. As 
expected, neither WT nor WAS−/− nTreg cells proliferated 
(Fig. 5 a) or produced TGF-β (Fig. 5 b) in response to anti-
CD3 mAbs alone. Furthermore, in contrast to WT nTreg 
cells, WAS−/− nTreg cells failed to proliferate and secrete 
TGF-β after activation with anti-CD3 plus anti-CD28 
mAbs (Fig. 5, a and b). The addition of exogenous IL-2 to 
anti-CD3 or anti-CD3 plus anti-CD28 mAbs stimulation 
induced comparable proliferation of WT and WAS−/− nTreg 
cells (Fig. 5 a) and promoted TGF-β production, although at 
reduced levels in WAS−/− nTreg cells (Fig. 5 b). Neither 
WT nor WAS−/− nTreg cells produced IL-2, IL-4, IL-5, 
IL-10, IFN-γ, and TNF-α after stimulation through the 
TCR/CD28 (not depicted). These data show that WAS−/− 
nTreg cells have a major activation defect downstream of the 
TCR and the CD28 receptor, and that proliferation, but not 
TGF-β production, is fully restored by the addition of exog-
enous IL-2. To determine whether WAS−/− nTreg cells 
have a higher threshold for TCR-mediated activation as 
compared with WT nTreg cells, we measured TCR down-
regulation after stimulation with increasing doses of anti-
CD3 mAbs. Both WT nTreg cells and eff   ector T cells 
down-regulated CD3 in a comparable dose-dependent man-
ner (Fig. 5 c). CD3 was also down-regulated in WAS−/− 
nTreg cells and eff  ector T cells, but higher doses of anti-
CD3 mAbs were required to obtain levels of down-regula-
tion similar to those observed in WT cells (Fig. 5 c). We 
next investigated whether the impaired regulatory function 
of WAS−/− nTreg cells could depend on the strength of 
TCR stimulation. WT eff  ector T cells were suppressed by 
WT nTreg cells in an anti-CD3 mAb dose-dependent man-
ner (Fig. 5 d). On the other hand, WAS−/− nTreg cells had 
a reduced suppressive ability compared with WT nTreg cells 
at the dose of 1 μg/ml, but the suppressive capacity was 
  enhanced when the anti-CD3 mAb dose was increased (Fig. 
5 d). However, the suppressive activity of WAS−/− nTreg 
cells could never reach normal levels (Fig. 5 d). Subsequently, 
increasing doses of anti-CD3 mAbs were used to activate 
WAS−/− eff  ector T cells to determine whether higher levels 
of activation render these cells more prone to nTreg cell–
mediated suppression. WAS−/− eff  ector T cells failed to 
  proliferate after stimulation with 1 μg/ml anti-CD3 mAbs 
Table I.  WAS gene mutations and clinical status of WAS patients
Patient Age (yr)a Mutation 
type
gDNA 
mutation
Protein 
change
Scoreb Thrombo-
cytopenia
T cell 
lymphopenia
Eczema Infections Autoimmunity
WAS1 24 Splice 
Intron 9
IVS9 +2 del 
tgag
ND 4 Yes No Mild Severe HSV, 
pneumonia
No
WAS4 23 Deletion 
Exon 6
570del t fs stop 
aa260
5Y e s c Yes Mild Various and 
recurrent 
infections
Vasculitis, arthritis, 
IgA nephropathy
WAS13 13.8 Missense 
Exon 1
150t>c L39P 2 Yesc Yes Mild No No
WAS14 1.8 Missense 
Exon 4
431g>a E133K 5 Yes Yes Mild No Colitis, vasculitisd
WAS17 2.8 Splice 
Intron 8
IVS8 +1 del 
gtga
fs stop 
aa246
4 Yes No Severe Recurrent otitis, 
pneumonia
No
WAS21 18 Missense 
Exon 7
741c>g A236G 2 Yesc Yes No Recurrent otitis No
WAS22 19 Missense 
Exon 2
201c>t A56V 1 Yes No No No No
fs, frameshift; del, deletion; IVS, intervening sequence (intron); ND, not determined.
aAge refers to the time of blood sampling.
bDisease score is given according to the classifi  cation reported previously (reference 34).
cSplenectomized.
dPatient undergoing therapy with prednisone.JEM VOL. 204, February 19, 2007  375
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(not depicted). At the dose of 10 μg/ml anti-CD3 mAbs, 
WAS−/− nTreg cells suppressed WAS−/− eff  ector T cells less 
effi   ciently than WT nTreg cells (Fig. 5 e). An increase in the 
anti-CD3 mAbs dose (30 μg/ml) led to comparable levels of 
suppression of WAS−/− eff  ector T cells by WT and WAS−/− 
nTreg cells (Fig. 5 e), although the suppressive activity was 
lower than that observed with WT eff  ector T cells. Overall, 
these data indicate that the suppressive defect of WAS−/− 
nTreg cells can depend both on the strength of TCR stimu-
lation and on the dysfunction of WAS−/− eff  ector T cells, 
suggesting an important role of WASP in both eff  ector and 
regulatory T cells.
Normal percentage of CD4+CD25+FOXP3+ nTreg cells 
in the blood of WAS patients
To our knowledge, the role of WASP in the generation and 
function of human nTreg cells has never been studied. As 
observed in murine cells, levels of WASP expression in 
CD4+CD25+ and CD4+CD25− T cells from the blood of 
healthy donors (HDs) were comparable (not depicted). To 
investigate the role of WASP in the generation of human 
nTreg cells, we analyzed CD4+CD25+FOXP3+ T cells from 
the peripheral blood of seven WAS patients of diff  erent ages 
and diff  erent clinical scores (Table I). Percentages of FOXP3+ 
cells among CD4+ T cells of WAS patients were either higher 
or comparable to those observed in HDs (Fig. 6 a). Overall 
analysis revealed a slight increase in FOXP3+ cells within 
Figure 6.  Immunophenotype of nTreg cells from human peripheral 
blood. (a) CD4+FOXP3+ cells in the peripheral blood of WAS patients. 
PBMCs from four representative HDs and seven WAS patients (WAS) were 
stained with anti-CD4 and anti-FOXP3 mAbs. Results shown are gated on 
the CD4+ T cells. Numbers indicate the percentages of FOXP3+ cells 
among CD4+ T cells. (b) Percentage of FOXP3+ cells (left), CD25+FOXP3+ 
cells (middle), and CD25− FOXP3+ cells (right) among CD4+ T cells of HDs 
(n = 16) and WAS patients (n = 7). Bars represent the median value for 
each group. 
Figure 7.  Allogeneic suppression by human nTreg cells. (a and b) 
Ability of nTreg cells freshly isolated from WAS patients and HDs to sup-
press allogeneic CD4+CD25− effector T cells from HDs. Effector T cells 
were cultured in the presence of nTreg cells at the indicated ratio and 
stimulated with CD3-depleted irradiated allogeneic APCs and anti-CD3 
mAbs for 72 h (HD1 and WAS4), anti-CD3 mAbs plus anti-CD28 mAb–
coated beads for 72 h (HD2 and WAS14), or anti-CD3 mAbs plus anti-
CD28 mAb–coated beads for 120 h (HD4 and WAS17). Proliferation was 
measured by [3H]thymidine incorporation (a), and IFN-γ secretion was 
measured by cytometric bead array (b). Filled bars, activated effector T 
cells (abbreviated as E); gray bars, activated effector T cells in the presence 
of nTreg cells isolated from HDs; dashed bars, activated effector T cells in 
the presence of nTreg cells isolated from WAS patients; dotted bars, acti-
vated nTreg cells alone. Percentages of suppression are indicated. (c and d) 
Cumulative graph of allogeneic suppression of proliferation (c) and 
IFN-γ production (d) at the indicated effector T cell/nTreg cell ratio. Dots 
represent percentage of suppression of each HD or WAS patient, and bars 
depict the respective median value. *, P < 0.05, Mann-Whitney test. 376  ROLE OF WASP IN CD4+CD25+FOXP3+ NTREG CELLS | Marangoni et al.
  patients’ CD4+ T lymphocytes, which is mainly due to an 
increase in CD4+CD25+FOXP3+ T cells (Fig. 6 b). The MFI 
values of CD25 and FOXP3 in CD4+ T cells from WAS 
  patients were comparable to those measured in HDs (not 
  depicted). These results indicate that WAS patients have a 
normal or increased proportion of circulating nTreg cells.
Defective suppressor activity of nTreg cells 
from WAS patients
Next, we investigated whether nTreg cells from WAS 
patients were able to suppress normal allogeneic eff  ector T cells. 
nTreg cells isolated from three WAS patients failed to sup-
press proliferation of allogeneic eff  ector T cells (Fig. 7 a), 
whereas suppression of IFN-γ production was reduced 
in two out of three WAS patients and completely defec-
tive in the third patient (Fig. 7 b). As expected, nTreg cells 
isolated from HDs had signifi  cant suppressor activity toward 
normal allogeneic CD4+CD25− eff  ector T cells, resulting 
in reduced proliferation (Fig. 7 a) and IFN-γ secretion (Fig. 
7 b). Upon stimulation, nTreg cells from WAS patients and 
HDs were anergic and failed to proliferate (Fig. 7 a) and 
to produce  IFN-γ (Fig. 7 b). Analysis of all experiments 
  performed showed that nTreg cells from WAS patients were 
consistently impaired in their ability to suppress prolifera-
tion of allogeneic targets (Fig. 7 c), whereas a residual sup-
pression of IFN-γ production could be detected (Fig. 7 d). 
We also tested the suppressor activity of nTreg cells from 
WAS patients toward autologous CD4+CD25− eff  ector T 
cells. Although control nTreg cells strongly suppressed the 
proliferation (Fig. 8 a) and IFN-γ secretion (Fig. 8 b) of 
autologous eff  ector T cells, nTreg cells from two WAS 
  patients tested had no signifi  cant suppressive eff  ects on cell 
proliferation (Fig. 8 a) and IFN-γ secretion (Fig. 8 b) by 
autologous eff  ector T cells. Overall, we conclude that nTreg 
cells from WAS patients were impaired in suppressing both 
proliferation (Fig. 8 c) and IFN-γ production (Fig. 8 d) of 
autologous targets.
Collectively, these data demonstrate that nTreg cells from 
WAS patients are strongly impaired in their suppressor activ-
ity toward both autologous and allogeneic targets.
DISCUSSION
In this study, we identify WASP as a key molecule for 
the optimal function of human and murine nTreg cells. 
WASP appears to be dispensable for thymic development and 
steady-state distribution of nTreg cells to the periphery. 
However, WASP is required for the TCR/CD28-triggered 
proliferation, the TGF-β production, and the suppressive 
function of nTreg cells. Given the key role played by these 
cells in maintaining peripheral tolerance, our data suggest that 
nTreg cell dysfunction might contribute to the high suscepti-
bility of WAS patients to develop allergy and multiple auto-
immune disorders.
Normal proportions of nTreg cells were found in the thy-
mus of WAS−/− mice, and the induction of Foxp3 expression 
occurred at the expected stage of thymocyte maturation. In 
addition, no abnormalities in thymic architecture, including 
the ratio between cortical and medullary areas and the 
number of Hassal’s corpuscles, were observed in WAS−/− 
mice (not depicted). The normal thymic diff  erentiation of 
WASP-defi  cient nTreg cells suggests that mechanisms of 
positive and negative selection of T cells with high-affi   nity 
TCR are preserved, including the TCR-dependent conver-
sion of autoreactive T cells into nTreg cells (5). This hypo-
thesis is consistent with a minor role of WASP in thymic T cell 
diff  erentiation, as suggested by previous studies in C57BL/6 
WAS−/− mice (45) and in patients (46).
Figure 8.  Autologous suppression by human nTreg cells. 
(a and b) Ability of nTreg cells freshly isolated from WAS patients and HDs 
to suppress autologous CD4+CD25− effector T cells. Effector T cells were 
cultured in the presence of nTreg cells at the indicated ratio and stimu-
lated with CD3-depleted irradiated allogeneic APCs and anti-CD3 mAbs for 
72 h (HD1 and WAS4), or with anti-CD3 mAbs plus anti-CD28 mAb–
coated beads for 120 h (HD5 and WAS21). Proliferation was measured 
by [3H]thymidine incorporation (a), and IFN-γ secretion was measured by 
cytometric bead array (b). Filled bars, activated effector T cells (abbrevi-
ated as E); gray bars, activated effector T cells in the presence of nTreg 
cells isolated from HDs; dashed bars, activated effector T cells in the pres-
ence of nTreg cells isolated from WAS patients; dotted bars, activated 
nTreg cells alone. Percentages of suppression are indicated. (c and d) 
  Cumulative graph of autologous suppression of proliferation (c) and IFN-γ 
production (d) at the indicated effector T cell/nTreg cell ratio. Dots repre-
sent percentage of suppression of each HD or WAS patient, and bars de-
pict the respective median value. JEM VOL. 204, February 19, 2007  377
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nTreg cells generated in the thymus undergo a robust 
  peripheral expansion that is mainly dependent on paracrine 
delivery of IL-2 by activated T cells and possibly DCs (47). 
The IL-2–IL-2R axis appears to be dispensable during thymic 
development, but it is required for the survival of nTreg cells 
in the periphery (14, 15). Although WAS is characterized by 
defective IL-2 production by T cells (41–44), no reduction in 
the relative numbers of nTreg cells in the spleens of WAS−/− 
mice was observed. These fi  ndings suggest that low levels of 
IL-2 in WAS−/− mice are suffi   cient to provide the appropri-
ate survival signals to peripheral nTreg cells. Although nor-
mal numbers of nTreg cells were found in the spleens of 
WAS−/− mice, adoptive transfer of WAS−/− nTreg cells into 
WT or WAS−/− hosts resulted in no or reduced, respec-
tively, recovery of those cells in draining LNs after immuni-
zation. This defective engraftment of WAS−/− nTreg cells 
could be due to impaired migration, survival, and/or prolif-
eration, and it may be even more evident in the competitive 
environment represented by WT hosts. In a distinct WASP-
defi  cient murine strain, Maillard et al. (reference 48; p. 379 
of this issue) found decreased numbers of nTreg cells in the 
spleen, suggesting that the degree of defects in nTreg cell 
  homeostasis may depend on the genetic background of the 
WAS−/− mouse model.
We showed here that murine WASP-defi  cient  nTreg 
cells were impaired in their regulatory function. Indeed, in 
vitro experiments showed that WAS−/− nTreg cells had a 
signifi  cantly reduced capacity to suppress WT eff  ector T cell 
proliferation at every cell ratio tested. After strong TCR 
stimulation (30 μg/ml anti-CD3 mAbs), a residual suppressor 
activity of WAS−/− nTreg cells on WT eff  ector T cells could 
be detected, suggesting that the in vitro dysfunction of 
WAS−/− nTreg cells is mainly due to an activation defect. 
Previous studies have shown that the suppressor activity of 
nTreg cells directly depends on their activation through the 
TCR (8). Indeed, we clearly demonstrated that WAS−/− 
nTreg cells have a profound defect in TCR/CD28-mediated 
activation. Upon stimulation with anti-CD3 and anti-CD28 
mAbs, WAS−/− nTreg cell proliferation and TGF-β produc-
tion were abolished. It remains to be determined whether the 
defect in TGF-β production contributes to the dysfunctional 
nTreg cell activity.
Given the master role of WASP in immunological syn-
apse assembly, it is tempting to speculate that WASP contrib-
utes to the assembly of an activatory synapse in nTreg cells 
and that the lack of this protein prevents optimal TCR acti-
vation in nTreg cells. However, we showed that, in contrast 
to eff  ector T cells, murine nTreg cells failed to polarize F-actin 
and concomitantly WASP to the site of contact with anti-
CD3 mAb-loaded APCs or beads coated with anti-CD3 and 
anti-CD28 mAbs (not depicted). Therefore, a role of WASP 
cannot be demonstrated in this process. On the other hand, it 
cannot be excluded that nTreg cells assemble a structurally 
diff  erent immunological synapse, or that its assembly follows 
diff  erent kinetics. It is also possible that the activation and 
functional defects of WAS−/− nTreg cells are independent 
from immunological synapse formation and are due to   defects 
in signaling downstream of the TCR. The observation that 
defective suppressive function in WAS−/− nTreg cells was 
present at a dose of TCR stimulation leading to normal TCR 
internalization is consistent with the hypothesis that  additional 
defects in late TCR-mediated signaling may play a role in the 
activation of these cells (49).
The activation state of the eff  ector T cells may also play a 
role in the suppressor activity of nTreg cells. We showed that 
WT nTreg cells could normally suppress the proliferation of 
WAS−/− eff  ector T cells at the eff  ector T cell/nTreg cell 
  ratio of 1:0.16, but at lower ratios, the suppressor activity was 
reduced as compared with that observed in cultures with WT 
eff  ector T cells. These data suggest a lack of activatory signals 
by WAS−/− eff  ector T cells. WAS−/− nTreg cells’ failure to 
suppress autologous WAS−/− eff  ector T cells was even more 
profound than that of WT nTreg cells (ratio 1:1), supporting 
a greater dependence of the former on signals delivered by 
eff  ector T cells that are required for their activation. There-
fore, we propose that defective activation of WAS−/− eff  ec-
tor T cells, which leads to impaired production of IL-2, 
might further amplify the intrinsic defect of WAS−/− nTreg 
cells. In line with this hypothesis, a defective cytokine pro-
duction by eff  ector T cells isolated from patients with  immune 
dysregulation, polyendocrinopathy, enteropathy, X-linked 
syndrome was recently proposed to contribute to the dys-
function of nTreg cells in this disease (50). We found that 
WAS−/− nTreg cells were responsive to TCR/CD28 stimu-
lation in the presence of exogenous IL-2. In a   complementary 
study, administration of exogenous IL-2 to anti-CD3 mAb–
stimulated WAS−/− nTreg cells could strongly enhance 
their suppressive ability in vitro (48). Collectively, these 
  data suggest that in WAS−/− mice, conditions leading to 
non-optimal activation of eff  ector T cells and defective IL-2 
production might amplify the intrinsic activation defect of 
nTreg cells.
Recent data demonstrated that transfer of a non-antigen–
specifi  c WT nTreg cell population in normocytic mice was 
able to control antigen-specifi  c responses (51). In our study, 
we compared the ability of adoptively transferred WT versus 
WAS−/− nTreg cells to modulate an in vivo immune   response 
to OVA. WAS−/− nTreg cells transferred in WT recipients 
were not found in LNs draining the site of OVA immuni-
zation, and subsequently, modulation of the OVA-specifi  c 
  immune response was not observed. Redistribution of WAS−/− 
nTreg cells transferred in autologous WAS−/− recipients 
was reduced, and in this condition, down-modulation of 
the OVA-specifi  c immune response was still observed. It 
should be noted that in the immunization protocol used 
here, the proliferation of WAS−/− eff  ector T cells upon in 
vitro restimulation with OVA was signifi  cantly higher com-
pared with that observed in WT mice. This could be related 
to a status of spontaneous immune activation in WAS−/− 
mice, as illustrated by the presence of increased numbers of 
CD4+CD25+Foxp3− splenocytes. These conditions of potent 
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by WAS−/− nTreg cells, although the recall response of cells 
from WAS−/− mice treated with WAS−/− nTreg cells was 
still very high. These data do not exclude that functional 
  defects of WAS−/− nTreg cells may arise in vivo with diff  er-
ent antigens and in diff  erent settings, such as those presented 
in the complementary study by Maillard et al. (48) using a 
diff  erent WAS−/− mouse strain. Indeed, WAS−/− nTreg cells 
displayed a defective in vivo suppressor activity toward colitis 
induced by transfer of WT CD45RBhigh cells. WAS−/− nTreg 
cell defects may therefore be exacerbated during the develop-
ment of spontaneous infl  ammatory bowel disease (42).
Collectively, our data suggest that in WASP defi  ciency 
the impaired suppressor activity of nTreg cells may be due to 
multiple defects, including intrinsic defects in activation and 
TGF-β production, as well as defects in other cell types, 
which therefore determine the extent of the impairment in 
homeostasis and peripheral tolerance.
Importantly, the role of WASP in regulating nTreg cell 
function was confi  rmed by our study in WAS patients. In 
seven WAS patients of diff  erent ages and with diff  erent dis-
ease severity, we found that the percentages of circulating 
CD4+CD25+FOXP3+ nTreg cells were within or above 
normal range, excluding a selective defect in nTreg cell dif-
ferentiation and production. Increased frequency of FOXP3+ 
cells in the blood of two patients was attributed to an increase 
in the CD4+CD25−FOXP3+ cell population, as seen in the 
thymuses and spleens of WAS−/− mice. This population has 
been proposed to be a pool of tissue-homing nTreg cells (9). 
Therefore, the increase in this cell subset might refl  ect a 
  reduced ability of WAS−/− nTreg cells to migrate to periph-
eral nonlymphoid organs. The in vitro suppressor activity of 
WASP-defi  cient nTreg cells on proliferation was clearly 
  impaired, both toward allogeneic and autologous eff  ector 
T cells. nTreg cells from WAS patients (two out of two) also 
failed to suppress IFN-γ production by autologous eff  ectors, 
whereas a residual regulatory activity toward IFN-γ produc-
tion by allogeneic responder cells (two out of three patients) 
was observed. This is in line with a previous report showing 
that suppression of proliferation and cytokine production by 
nTreg cells isolated from patients with rheumatoid arthritis 
could occur independently (52).
Based on the results presented in this study, we hypothe-
size that one possible cause of autoimmunity and atopic dis-
ease in WAS patients is a functional defect of nTreg cells. 
Recent studies reported a compromised function of nTreg 
cells in several autoimmune diseases, including immune dys-
regulation, polyendocrinopathy, enteropathy, X-linked syn-
drome (50), multiple sclerosis (53), autoimmune polyglandular 
syndrome type II (54), rheumatoid arthritis (52), myasthenia 
gravis (55), and type 1 diabetes (56).
The similarities between our murine and human studies 
(normal steady-state distribution of nTreg cells in the periph-
ery with defective suppressor activity) validate the WAS−/− 
murine model for further investigation of the contribution of 
nTreg cell defects to autoimmunity. It will be particularly 
  interesting to study in this model how microbial triggers may 
act in concert with the functional defect in nTreg cells to lead 
to autoimmunity.
In conclusion, we show here that WASP is specifi  cally 
required for the activation and suppressive function of 
CD4+CD25+FOXP3+ nTreg cells of both human and murine 
origin, but not for their diff  erentiation. We propose that the 
functional failure of nTreg cells contributes to the develop-
ment of autoimmunity and atopic disease in WAS.
MATERIALS AND METHODS
Mice. C57BL/6 WAS−/− mice were provided by K.A. Siminovitch (Mt. 
Sinai Hospital, Toronto, Canada) (43). WAS−/−-CD45.1 mice were gener-
ated in our animal facility. No spontaneous colitis was observed in these 
mouse models. WT C57BL/6 and WT C57BL/6-CD45.1 control mice 
were purchased from Charles River Laboratories. All procedures were per-
formed according to protocols approved by the Animal Care and Use Com-
mittee of the San Raff  aele Scientifi  c Institute.
Patients and human cells. The detailed clinical status of the patients is 
  reported in Table I. Peripheral blood samples from WAS patients and age-
matched HDs were obtained following standard ethical procedures (includ-
ing informed consent) and with the approval of the San Raff  aele Scientifi  c 
Institute Internal Review Board. PBMCs were purifi  ed on Ficoll gradient 
(Nycomed Pharma A/S).
Immunophenotype and immunofl  uorescence analysis. The following 
mAbs were used for surface staining of murine cells: anti-CD4 (RM4-5), 
anti-CD8 (53–6.7), anti-CD24 (M1/69), anti-CD25 (PC61), anti-CD45.2 
(104), anti-CD45RB (16A), anti-CD62L (MEL14), and anti-CD69 
(H1.2F3), all from BD Biosciences. Intracytoplasmic staining was performed 
using the following mAbs: anti-WASP (B-9; Santa Cruz Biotechnology, 
Inc.), anti–CTLA-4 (UC10-4F10-11; BD Biosciences), and anti-GITR 
(108619; R&D Systems). The staining with anti-Foxp3 mAbs (FJK-16s; 
eBioscience) was performed according to the manufacturer’s instructions. 
For immunofl  uorescence staining, purifi  ed T cells were incubated for 20 
min with Orange-CMTMR–loaded CD90− splenocytes as APCs (at a 1:1 
cell ratio) in absence or presence of anti-CD3 mAbs (2C11; BD Biosci-
ences). Cells were transferred onto Poly-l-lysine–coated glass slides, fi  xed/
permeabilized, and stained with AlexaFluor633-conjugated Phalloidin (Invit-
rogen) and anti-WASP antibodies (H-250; Santa Cruz Biotechnology, Inc.), 
followed by AlexaFluor488-conjugated goat anti–rabbit antibodies. The sam-
ples were examined on a Carl Zeiss LSM 510 confocal microscope with an 
x63 Plan-Apochromat objective.
Human PBMCs were stained with anti-CD4 mAbs (SK3) and anti-
CD25 mAbs (2A3), all from BD Biosciences. FOXP3 expression was evalu-
ated using PHC101 mAbs from eBioscience.
nTreg cell activation assays. CD90+CD25− eff  ector T cells and CD4+CD25+ 
nTreg cells were purifi  ed from murine splenocytes by a combination of 
immunomagnetic beads (Miltenyi Biotec) and FACS sorting. Purity of 
CD4+CD25+ nTreg cells was ≥90% in all experiments. Cells were plated 
at 105 cells/well in the presence of the indicated dose of plate-bound anti-
CD3 mAbs (17A2; BD Biosciences) either alone or in combination with 
  either 1 μg/ml anti-CD28 mAbs (37.51; BD Biosciences) or 100 U/ml 
rhIL-2 (Chiron Corporation). Cell proliferation was measured after a 96-h 
stimulation by liquid scintillation counting. TGF-β secretion was measured 
by specifi  c ELISA (R&D Systems) on supernatants conditioned for 96 h. 
The Bio-Plex technology using the Mouse Th1/Th2 panel (all from Bio-
Rad Laboratories) was used to measure the levels of IL-10 and IL-5 (after a 
96-h stimulation), and IL-2, IL-4, IFN-γ, and TNF-α (after a 48-h stimula-
tion) in conditioned supernatants. TCR down-regulation was evaluated by 
FACS analysis on splenocytes previously stained with anti-CD4 and anti-
CD25 mAbs, and subsequently stimulated with the indicated dose of plate-
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In vitro suppression assays. Suppression assays using murine cells were 
performed as follows: CD90+CD25− eff  ector T cells were plated at 105 cells 
per well and cocultured with 105 (1:1 eff  ector T cell/nTreg cell ratio), 4 × 
104 (1:0.4 eff  ector T cell/nTreg cell ratio), or 1.6 × 104 (1:0.16 eff  ector T 
cell/nTreg cell ratio) CD4+CD25+ nTreg cells in the presence of the indi-
cated amount of plate-bound anti-CD3 mAbs. Cell proliferation was mea-
sured after a 96-h stimulation by liquid scintillation counting. Percentage of 
suppression was calculated as compared with eff  ector T cells.
For suppression assays using WAS patients’ cells, CD4+CD25+ nTreg 
cells and CD4+CD25− eff  ector T cells were isolated from PBMCs by FACS 
sorting. Cells from HDs were used as control: CD4+ T cells were purifi  ed 
either by FACS sorting or, alternatively, by immunomagnetic beads. In both 
cases, the purity of nTreg cells ranged from 80 to 95%, and the purity of 
  eff  ector cells was ≥95%. Suppression assays with purifi  ed human nTreg cells 
were performed as follows: 5 × 104 CD4+CD25− eff  ector T cells were 
stimulated by CD3-depleted APCs (irradiated at 6,000 rad) and 1 μg/ml of 
soluble anti-CD3 mAbs (Orthoclone OKT3; Janssen-Cilag). Alternatively, 
when very low numbers of nTreg cells were recovered, 104 eff  ector T cells 
were cocultured with nTreg cells and stimulated with beads coated with 
anti-CD3 and anti-CD28 mAbs (Dynal). For each lot of beads used, the 
  optimal responder/bead ratio and the optimal culture time were carefully 
determined. Suppressive activity of nTreg cells was assessed by coculture of 
eff  ector T cells with nTreg cells at diff  erent ratios. Proliferation was evalu-
ated by liquid scintillation counting, and IFN-γ secretion was evaluated on 
supernatants by the human Th1/Th2 cytokine cytometric bead array system 
(BD Biosciences). Values of IFN-γ in the supernatants were normalized to a 
number of 2 × 105 cells.
In vivo modulation of OVA-specifi  c immune response. nTreg cells 
from either WT or WAS−/− mice (carrying the CD45.2 allele) were   injected 
i.v. (1–1.5 × 106 per mouse) into WT or WAS−/− syngeneic mice. For 
tracking experiments, WT-CD45.1 and WAS−/−-CD45.1 mice were used 
as recipients. 1 d later, mice were immunized by footpad injection of 100 μg 
OVA (grade V; Sigma-Aldrich) emulsifi  ed in CFA (Sigma-Aldrich). 7–10 d 
later, donor-derived cells were tracked in draining and nondraining LNs, 
blood, spleen, lungs, and liver by staining with anti-CD45.2 mAbs. In 
  parallel, the in vitro recall response to OVA was tested as follows: total 
lymphocytes isolated from draining LNs were plated at 5 × 105 cells per 
well and cultured for 72 h with 5 μg/ml OVA. Cells were then pulsed 
with [3H]thymidine, and cell proliferation was measured by liquid scintilla-
tion counting.
Statistical analysis. Where data followed a normal distribution (checked 
by Kolmogorov-Smirnov test), experimental groups were compared with a 
two-tailed Student’s t test. Otherwise, a two-tailed Mann-Whitney test was 
used. p-values of <0.05 were considered signifi  cant.
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